ESC 365 - Naxos study: risk of bleeding with oral anticoagulants in non-valvular atrial fibrillation patients in France

ESC Premium Access

Naxos study: risk of bleeding with oral anticoagulants in non-valvular atrial fibrillation patients in France

Session: NOAC Dosing, Adherence and Treatment Effects

Topic: Oral Anticoagulation

Speaker: Professor N. Danchin (Paris, FR)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Professor Nicolas Danchin

Saint Joseph Hospital, Paris (France)

18 presentations

1 follower

5 more presentations in this session

The effect of computer decision support on optimizing appropriate dosing of novel oral anticoagulant therapy in the IMPACT-AF study

Speaker: Doctor J. Cox (Halifax, CA)

Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomised clinical trial

Speaker: Doctor A. Tzikas (Thessaloniki, GR)

Real-world adherence to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation measured by an electronic medication event monitoring system

Speaker: Doctor M. Delesie (Hasselt And Antwerp, BE)

Comparison between non-vitamin K antagonist oral anticoagulants versus warfarin for the risk of dementia in Asian patients with non-valvular atrial fibrillation

Speaker: Doctor S. Lee (Seoul, KR)

Compliance of atrial fibrillation treatment with the ABC pathway in patients with concomitant diabetes mellitus in the Middle East based on the Gulf SAFE registry

Speaker: Doctor J. Gumprecht (Zabrze, PL)

Access the full session

NOAC Dosing, Adherence and Treatment Effects

Speakers: Professor N. Danchin, Doctor J. Cox, Doctor A. Tzikas, Doctor M. Delesie, Doctor S. Lee...

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources